Genesis Molecular AI vs Numerion Labs (2026)
Both develop small molecules on AI platforms built around structure. Genesis Molecular AI runs GEMS, with generative models for ideation, multitask models for drug properties and agents for routine steps, and its Pearl model, released in October 2025, predicts protein ligand structures and can be fine tuned on a program's own data. It publishes measured results against named baselines. Numerion Labs, formerly Atomwise, works in immune and inflammatory disease on COSMOS, APEX and EXPO, and its Atomwise era AIMS study found novel hits for 235 of 318 academic targets. Both work mainly through their own programs and partnerships rather than software sales.
- Pearl, a protein ligand structure model trained on proprietary physics based synthetic data and fine tunable on a program's data.
- Measured results with denominators against named baselines.
- Agents that orchestrate routine work while chemists keep the decisions.
- A prospective published screening record: novel hits for 235 of 318 academic targets in the AIMS study (Scientific Reports, 2024).
- A current platform of COSMOS, APEX and EXPO, aimed at immune and inflammatory disease.
- Enumeration at scale, described in October 2025 research with NVIDIA.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Genesis Molecular AI and Numerion Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Genesis Molecular AI | Numerion Labs |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | Not recorded |
| Headquarters | Burlingame, CA | San Francisco, CA |
| Website | genesis.ml | numerionlabs.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Stanford spinout, now trading as Genesis Molecular AI, building GEMS, a small molecule discovery platform its own chemists and its partners' programs run on. GEMS combines generative models for molecule ideation, multitask models for absorption, distribution, metabolism and excretion prediction, and agents that orchestrate routine steps while chemists interrogate predictions and decide what to synthesize.
Source: AI Health Index, September 2026
Numerion Labs, formerly known as Atomwise, is a San Francisco AI drug discovery company developing small molecules for immune and inflammatory disease, led by chief executive Steve Worland.
Source: AI Health Index, September 2026
Questions buyers ask
How do Genesis Molecular AI and Numerion Labs handle patient data?
For Genesis Molecular AI, the company's site carries no privacy policy, no terms of use and no data handling statement of any kind; the footer offers navigation and a contact page and nothing else.
With Numerion Labs, the sensitive material is a partner's own targets, compound data and assay results, the project data EXPO adapts its models to. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Genesis Molecular AI and Numerion Labs leave to the clinician?
In Genesis Molecular AI's case, the platform's own account of the workflow puts the chemist at the decision: models generate candidates and predict properties, agents orchestrate the routine steps and surface trade-offs, and the chemist interrogates the predictions, visualizes the structures, filters and sorts, and decides what to synthesize.
For Numerion Labs, the picks were then screened in the laboratory: by the academic collaborators in the AIMS program, and, for internal programs, at contract research organizations after synthesis at Enamine. On the current platform, EXPO optimization algorithms carry novel binders toward drug candidates, and the chief executive describes APEX as letting chemist and computer work together in real time. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Neither publishes prices, and Numerion's strongest published result predates its rename.
Ask both which published results came from the platform version you would use.